Natera, Inc. - Common Stock · Transaction Sep 22, 2025 · Filed Oct 15, 2025 · $1,001 to $15,000
NASDAQ NMS - GLOBAL MARKET · NTRA
0.00% · $0.0000 · Vol Not reported
Market closed · last close shown
Natera Inc
Biotechnology
$408.47
Follow $NTRA
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $NTRA by emailVeridion Score
BETAHIGH CONF · 6 of 6 factors measuredThu Oct 1 · last completed session · Pre-market · regular session opens 9:30 ET · NTRA
MethodologyNTRA
Natera Inc
Thu Oct 1 · last completed session · Pre-market · regular session opens 9:30 ET
Upper range
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
60/ 100
Veridion Score
Upper range · HIGH confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: HIGH · 6 of 6 factors measured · Thu Oct 1 · last completed session · Pre-market · regular session opens 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is NTRA moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Natera Inc
SERVICES-MEDICAL LABORATORIESListed since
2015
Employees
6K
Country
US
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$408.47
Last session
Day high
$408.47
Last session
Day low
$408.47
Last session
Previous close
$408.47
52W high
$414.52
-1.46% from high
52W low
$160.21
98% of range
Market cap
$58.9B
EPS
$-1.3652
Beta
1.08
Shares out
144.1M
Avg volume
1.5M
VWAP
$408.47
Last session
Price history computed in-house
1W
-0.99%
1M
+25.62%
3M
+46.24%
1Y
+154.96%
YTD
+78.30%
SMA 50 $328.16 · above
SMA 200 $248.14 · above
52W position 98%
NTRA overview
Related filings and maps
Public disclosures
Congress activity in NTRA
Official filing ↗
Natera, Inc. - Common Stock · Transaction Aug 22, 2025 · Filed Sep 5, 2025 · $1,001 to $15,000
Natera, Inc. - Common Stock · Transaction Jul 22, 2025 · Filed Aug 11, 2025 · $1,001 to $15,000
Natera, Inc. - Common Stock · Transaction Nov 20, 2024 · Filed Dec 5, 2024 · $1,001 to $15,000
Natera, Inc. · Transaction Apr 10, 2023 · Filed May 19, 2023 · $1,001 to $15,000
Federal contracts
NTRA contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for NTRA in this window.
Lobbying spend
NTRA lobbying filings, year to date.
Registered lobbying filings matched to Natera Inc.
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for NTRA in this window.
Analyst ratings
Sovereign unlock shows live analyst consensus for NTRA.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.